A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
Dec 24, 2019
―
Trastuzumab, Letrozole, Atezolizumab, Pelareorep
Breast Cancer
Early Phase I
Terminated
A Window-of-opportunity Study of Pelareorep in Early Breast Cancer
Sep 23, 2019
―
Gemcitabine, Cisplatin, Reolysin®
Muscle-Invasive Transitional Cell Carcinoma Of The Bladder
Phase I
Withdrawn
Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder
Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
Jan 07, 2011
―
Carboplatin, Paclitaxel, Reolysin
Metastatic Or Recurrent Squamous Cell Carcinoma Of The Lung
Phase II
Completed
A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
Oct 15, 2009
―
Carboplatin, Paclitaxel, Reolysin®
Carcinoma, Non-Small Cell Lung
Phase II
Completed
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation
Mar 12, 2009
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Oncolytics Biotech (ONCY) have in its pipeline
ONCY is currently developing the following drugs: Paclitaxel, Avelumab, Pelareorep, Trastuzumab, Letrozole, Atezolizumab, Pelareorep, Gemcitabine, Cisplatin, Reolysin®. These drug candidates are in various stages of clinical development as the company works toward FDA approval.